Home › Therapeutic areas › Oncology › Colorectal Cancer
Colorectal Cancer (27 companies)
Companies with an active program in Colorectal Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 1 | Phase 2 | $134M | 10 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $880M | 10 |
| BCAX | Bicara Therapeutics | Oncology | 1 | Phase 2 | $572M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $164M | 6 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $338M | 3 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $477M | 7 |
| ELTX | Elicio Therapeutics | Oncology | 1 | Phase 2 | $42.7M | 6 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.60B | 15 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.24B | 6 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $82.0M | 13 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $4.55B | 17 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $64.5M | 7 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 2 | Phase 2 | $52.8M | 8 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | $56.1M | 3 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | $41.6B | 11 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $852M | 7 |
| VSTM | Verastem | Oncology | 1 | Approved | $1.06B | 5 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | $2.09B | 12 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
No companies match.